Limits...
Controlled-release approaches towards the chemotherapy of tuberculosis.

Saifullah B, Hussein MZ, Hussein Al Ali SH - Int J Nanomedicine (2012)

Bottom Line: For multidrug-resistant TB, patients must take second-line anti-TB drugs for 18-24 months and many adverse effects are associated with these drugs.DDSs reduce the adverse effects of drugs and their dosing frequency as well as shorten the treatment period, and hence improve patient compliance.In addition, targeted delivery systems may be useful in dealing with extensively drug-resistant TB because many side effects are associated with the drugs used to cure the disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

ABSTRACT
Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis, is notorious for its lethality to humans. Despite technological advances, the tubercle bacillus continues to threaten humans. According to the World Health Organization's 2011 global report on TB, 8.8 million cases of TB were reported in 2010, with a loss of 1.7 million human lives. As drug-susceptible TB requires long-term treatment of between 6 and 9 months, patient noncompliance remains the most important reason for treatment failure. For multidrug-resistant TB, patients must take second-line anti-TB drugs for 18-24 months and many adverse effects are associated with these drugs. Drug-delivery systems (DDSs) seem to be the most promising option for advancement in the treatment of TB. DDSs reduce the adverse effects of drugs and their dosing frequency as well as shorten the treatment period, and hence improve patient compliance. Further advantages of these systems are that they target the disease area, release the drugs in a sustained manner, and are biocompatible. In addition, targeted delivery systems may be useful in dealing with extensively drug-resistant TB because many side effects are associated with the drugs used to cure the disease. In this paper, we discuss the DDSs developed for the targeted and slow delivery of anti-TB drugs and their possible advantages and disadvantages.

Show MeSH

Related in: MedlinePlus

Scanning electron micrograph of spray-dried capreomycin dry powder. Note: Scale bar = 5 μm.Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830–2836. Reproduced with permission from American Society for Microbiology.38
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3472697&req=5

f4-ijn-7-5451: Scanning electron micrograph of spray-dried capreomycin dry powder. Note: Scale bar = 5 μm.Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830–2836. Reproduced with permission from American Society for Microbiology.38

Mentions: Garcia-Contreras et al38 designed low-density porous capreomycin sulfate particulates for efficient delivery in lungs with increased bioavailability and the same ability to reduce the TB count in lungs as that accomplished with injection. The pharmacokinetic factors after the administration of capreomycin particles in lungs were established. Garcia-Contreras and Hickey assayed the usefulness of these particles in a small-aerosol inoculum TB model in guinea pig, establishing that capreomycin particles had no undesirable effects.37 Garcia-Contreras and Hickey’s study reveals that treatment of TB by respiration of capreomycin particles has no side effects and hence is safe to use and effective.37Figure 4 shows a scanning electron microscope image of capreomycin dry powder.


Controlled-release approaches towards the chemotherapy of tuberculosis.

Saifullah B, Hussein MZ, Hussein Al Ali SH - Int J Nanomedicine (2012)

Scanning electron micrograph of spray-dried capreomycin dry powder. Note: Scale bar = 5 μm.Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830–2836. Reproduced with permission from American Society for Microbiology.38
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3472697&req=5

f4-ijn-7-5451: Scanning electron micrograph of spray-dried capreomycin dry powder. Note: Scale bar = 5 μm.Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830–2836. Reproduced with permission from American Society for Microbiology.38
Mentions: Garcia-Contreras et al38 designed low-density porous capreomycin sulfate particulates for efficient delivery in lungs with increased bioavailability and the same ability to reduce the TB count in lungs as that accomplished with injection. The pharmacokinetic factors after the administration of capreomycin particles in lungs were established. Garcia-Contreras and Hickey assayed the usefulness of these particles in a small-aerosol inoculum TB model in guinea pig, establishing that capreomycin particles had no undesirable effects.37 Garcia-Contreras and Hickey’s study reveals that treatment of TB by respiration of capreomycin particles has no side effects and hence is safe to use and effective.37Figure 4 shows a scanning electron microscope image of capreomycin dry powder.

Bottom Line: For multidrug-resistant TB, patients must take second-line anti-TB drugs for 18-24 months and many adverse effects are associated with these drugs.DDSs reduce the adverse effects of drugs and their dosing frequency as well as shorten the treatment period, and hence improve patient compliance.In addition, targeted delivery systems may be useful in dealing with extensively drug-resistant TB because many side effects are associated with the drugs used to cure the disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

ABSTRACT
Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis, is notorious for its lethality to humans. Despite technological advances, the tubercle bacillus continues to threaten humans. According to the World Health Organization's 2011 global report on TB, 8.8 million cases of TB were reported in 2010, with a loss of 1.7 million human lives. As drug-susceptible TB requires long-term treatment of between 6 and 9 months, patient noncompliance remains the most important reason for treatment failure. For multidrug-resistant TB, patients must take second-line anti-TB drugs for 18-24 months and many adverse effects are associated with these drugs. Drug-delivery systems (DDSs) seem to be the most promising option for advancement in the treatment of TB. DDSs reduce the adverse effects of drugs and their dosing frequency as well as shorten the treatment period, and hence improve patient compliance. Further advantages of these systems are that they target the disease area, release the drugs in a sustained manner, and are biocompatible. In addition, targeted delivery systems may be useful in dealing with extensively drug-resistant TB because many side effects are associated with the drugs used to cure the disease. In this paper, we discuss the DDSs developed for the targeted and slow delivery of anti-TB drugs and their possible advantages and disadvantages.

Show MeSH
Related in: MedlinePlus